Mental Health Book

Hallucinogen Use Disorders

Inhalants

http://www.fpnotebook.com/

NBOMe

Aka: NBOMe, N-Benzylated Phenylethylamine, 25C-NBOMe
  1. See Also
    1. Hallucinogen
    2. Synthetic Marijuana
    3. Synthetic Cathinone (Bath Salts)
    4. Chemical Dependency
    5. Substance Abuse Evaluation
    6. Agitated Delirium
  2. Mechanism
    1. Synthetic Hallucinogen (2C) acting at 5-HT2A receptor (potent Serotonin 2A receptor agonists)
    2. Phenethylamine pharmacore increases neurotransmitter levels with Sympathomimetic effects
    3. Originally developed in 2003 as Serotonin 2A receptor agonist as traceable agent for PET Scan
  3. Preparations
    1. Formulations
      1. Most common formulation of three produced: 25I-NBOMe
      2. Forms include liquid, powder, capsule, tablet, spray
      3. Used orally most frequently (mixed with solvent on blotting paper)
      4. Also used sublingual, intranasal, rectal, smoked or injected
      5. Typically sold for $7-10 per dose
    2. Street Names
      1. N-Bomb
      2. Smiles
  4. Pharmacokinetics
    1. Minimum effective dose: 50 mcg SL
    2. Onset: 20 minutes
    3. Duration: 3-13 hours
  5. Symptoms: Desired Effects
    1. Hallucinations
    2. Dissociation
    3. Euphoria
  6. Labs
    1. Serum Creatinine Kinase
    2. White Blood Cell Count (Leukocytosis)
    3. Serum Glucose (Hyperglycemia)
    4. Serum transaminases (increased)
    5. Serum Creatinine (increased)
  7. Adverse effects
    1. Cardiovascular effects
      1. Tachycardia
      2. Hypertension
    2. Neuropsychiatric effects
      1. Agitation and aggression (85% of patients)
      2. Delirium
      3. Paranoia
      4. Altered Mental Status
      5. Hyperreflexia
      6. Clonus
      7. Seizures (75%)
    3. Miscellaneous
      1. Tongue Paresthesias (related to blotting paper contact reaction)
  8. Complications
    1. Hyperthermia
    2. Pulmonary edema
    3. Death
    4. Status Epilepticus (with anoxic brain injury)
  9. Management
    1. Benzodiazepines
      1. Agitation or Psychosis
      2. Seizures
    2. IV Fluids
      1. Prevent or treat Rhabdomyolysis
    3. Cooling measures
      1. Manage hyperthermia
  10. References
    1. Bersani (2014) Biomed Res Int 2014: 734749
      1. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106087/
    2. Haynes, Meadors and Yuan (2016) Crit Dec Emerg Med 30(2): 3-9
    3. Laskowski (2015) J Med Toxicol 11(2):237-41 +PMID:25387562 [PubMed]

You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree